Blood Test for Pancreatic Cancer Risk
Author Information
Author(s): León-Letelier Ricardo A, Chen Yihui, Ballaro Riccardo, Irajizad Ehsan, Do Kim-An, Maitra Anirban, Zhang Jianjun, Schmidt C Max, Fahrmann Johannes F.
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Can a blood-based metabolite signature predict the 5-year risk of pancreatic cancer?
Conclusion
The study developed a blood-based metabolite panel that can identify individuals at high risk of developing pancreatic cancer.
Supporting Evidence
- Screening high-risk individuals can improve survival outcomes for pancreatic cancer.
- The metabolite panel includes both microbial and host-derived metabolites.
- Individuals with a combined metabolite and CA19-9 score in the top 2.5th percentile have a 5-year risk of pancreatic cancer greater than 13%.
Takeaway
Researchers created a blood test that can help find people who are likely to get pancreatic cancer, so they can be watched more closely.
Methodology
The study used pre-diagnostic plasma samples from 172 pancreatic cancer cases and 863 matched controls to develop a metabolite panel.
Potential Biases
Potential biases due to lack of control over dietary factors and missing data on certain health conditions.
Limitations
Information on chronic pancreatitis, fasting status, and food intake was not available, which may affect metabolite levels.
Participant Demographics
Participants included individuals from high-risk groups, such as those with new-onset diabetes and chronic pancreatitis.
Statistical Information
P-Value
3.13
Confidence Interval
95% CI: 2.08–4.98
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website